Core Viewpoint - AbbVie Inc. is recognized as one of the 12 best long-term stocks to buy, despite facing some challenges in clinical trials [1]. Group 1: Market Analysis - Citi has adjusted its price target for AbbVie to $230 from $235 while maintaining a Neutral rating, indicating a more supportive backdrop for the biopharma sector in 2026 due to manageable earnings expectations and reduced policy-related risks [2]. - The overall sentiment in the biopharma space suggests that earnings may exceed previous fears, contributing to a more favorable investment environment [2]. Group 2: Clinical Developments - AbbVie and Genmab's blood cancer drug, epcoritamab, did not demonstrate a statistically significant survival benefit in a late-stage study involving 483 patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - Despite the lack of clear survival benefits, the study revealed positive outcomes, such as a higher number of patients achieving undetectable cancer levels, longer response durations, and improved time before requiring further treatment [4]. - Epcoritamab is already approved in several countries for other lymphoma indications, marketed as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5].

UnitedHealth Despite all the negative sentiment this week, some retail investors were still optimistic about MSFT's growth. The stock had a 52-week range of $344.79 to $555.45, trading around $433 to $435 per share, as of the publication of this article. It rose 4.46% over the year and declined by 15.54% over the last six months. The stock had a weaker price trend in the short, medium, and long terms, with a solid quality ranking, as per Benzinga's Edge Stock Rankings. Some retail investors said MSFT should ...

Materials suppliers Entegris and Qnity aren't household names, but they benefit from both the AI frenzy and a broader chip-sector recovery. ...

In the age of cloud computing, it's easy to forget that IBM (NYSE: IBM) still sells its hulking mainframe systems. Following IBM's fourth-quarter earnings report, it's clear that the mainframe business is not only surviving but also thriving. Here's an incredible fact IBM CFO Jim Kavanaugh disclosed during the earnings call: IBM's mainframe business recorded its best fourth quarter revenue in more than 20 years. Revenue soared 61% year over year, adjusted for currency, driving a 17% increase in the infras ...

I have owned Apple (NASDAQ: AAPL) for many years. The tech titan has grown into my top holding. While my Apple position is only 4% of my total investment portfolio, it's a whopping 27% of my ROTH IRA. I'd like to lower my exposure in that account. However, instead of selling some of my Apple stock, I'm using it to make passive income through a unique strategy. Here's a look at my trade and how you can more easily mimic this income strategy through a passive investment in an exchange-traded fund (ETF). Whe ...

Group 1 - BofA has lowered the price target on Peloton (PTON) to $9 from $11 while maintaining a Buy rating ahead of the fiscal Q2 results report on February 5 [1] - The firm remains optimistic about Peloton's product-led strategy, AI integration, and expanding ecosystem [1] - The reduction in price target is attributed to expectations of higher churn following the price increases implemented in October [1]

Core Viewpoint - Procter & Gamble (PG) is experiencing a slower recovery path, with analysts expecting subdued growth in the coming years due to various market pressures [2][3]. Financial Performance - For the three months ended December 31, P&G reported net sales of approximately $22.21 billion, which is a 1% year-over-year increase but slightly below the expected $22.28 billion [6]. - Adjusted profit exceeded forecasts, driven by strong demand for higher-end haircare and beauty products [3]. - Core gross margin has declined for five consecutive quarters, influenced by tariffs and investments in diverse pack sizes for cost-conscious consumers [6]. Market Conditions - The US government shutdown negatively impacted P&G's largest market, leading to sales declines across categories due to delayed food assistance payments affecting lower-income households [4]. - Sales volumes decreased in three of P&G's five reported categories, with only beauty showing growth as consumers continue to prioritize self-care [5]. - Overall sales volumes were significantly below the typical US growth range of 3% to 4% across categories [5]. Analyst Sentiment - TD Cowen downgraded P&G from Buy to Hold, raising the price target to $156 from $150, citing a likely prolonged turnaround period [2]. - Analysts predict organic sales growth to remain around 2% over the next two years, with limited pricing power and ongoing pressure on the Hispanic consumer [2].

Core Viewpoint - BofA analyst Andrew Didora has raised the price target for Southwest Airlines (LUV) to $42 from $37 while maintaining an Underperform rating on the shares, indicating skepticism about the execution of the company's plans [1] Group 1: Price Target and Rating - The price target for Southwest Airlines has been increased to $42 from $37 [1] - The Underperform rating on the shares remains unchanged [1] Group 2: Earnings Estimates - The analyst acknowledges a potential underestimation of earnings from the new credit card agreement [1] - The firm's EPS estimate for 2026 has been raised to $4.36 from $3.60 [1] Group 3: Market Sentiment - There is a belief that much of the positive sentiment has already been priced in following the stock's movement on earnings day [1]

Core Viewpoint - Horizon Space Acquisition II (HSPT) has postponed its extraordinary general meeting from February 3, 2026, to February 12, 2026, to allow more time for engagement with shareholders [1] Group 1 - The company aims to enhance communication with its shareholders during the additional time before the rescheduled meeting [1]

Group 1 - Benchmark raised the price target on Plexus (PLXS) to $220 from $195, maintaining a Buy rating on the shares [1] - The firm was surprised by the strength of the Q2 guidance and the upbeat tone around demand momentum for the remainder of FY26 and beyond [1]